title: MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.
authors.affiliation: Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
authors.forename: P
authors.initials: P
authors.lastname: de la Puente
authors.affiliation: Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
authors.forename: B
authors.initials: B
authors.lastname: Muz
authors.affiliation: Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.|Department of Pharmaceutical and Administrative Sciences, St Louis College of Pharmacy, St Louis, MO, USA.
authors.forename: A
authors.initials: A
authors.lastname: Jin
authors.affiliation: Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
authors.forename: F
authors.initials: F
authors.lastname: Azab
authors.affiliation: Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
authors.forename: M
authors.initials: M
authors.lastname: Luderer
authors.affiliation: Department of Pharmaceutical and Administrative Sciences, St Louis College of Pharmacy, St Louis, MO, USA.|Department of Pharmaceutics and Industrial Pharmacy, Cairo University Faculty of Pharmacy, Cairo, MO, Egypt.
authors.forename: N N
authors.initials: NN
authors.lastname: Salama
authors.affiliation: Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: Azab
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011728:Pyridones / Q000494:pharmacology* / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C558666:TAK 733